Alcon Inc.’s ALC growth is driven by its ... 20.8% growth and the S&P 500 composite’s 31.2% increase. The renowned pharmaceutical and medical device manufacturer has a market capitalization ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

In a report released on October 1, David Evans from Kepler Capital maintained a Buy rating on Roche Holding AG (RHHVF – Research ...

Medical device peers Alcon, Cooper Cos. and Johnson & Johnson own 25% to 40% of the market for contact lenses vs. 10% for Bausch + Lomb. In pharmaceuticals, AbbVie would encounter antitrust ...

Regarding distributions, we view Novartis’ dividends and share repurchases as about right. Novartis has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against other wonderful stocks to buy now ...

Even in areas of tech that have done better, bosses note that the war is undermining morale and productivity. What is more, ...

A potential sale of Bausch + Lomb presents a significant opportunity for Bausch Health. The deal could provide the company ...

Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of ...

In H2 of the year so far, there are signs that the S&P 500 index has been broadening beyond technology leadership and the ...